Medical officer leaves for unknown reasons; wonder what it signifies, if anything . . .
>>SOUTH SAN FRANCISCO, Calif., Nov. 22 /PRNewswire-FirstCall/ -- Renovis, Inc. (Nasdaq: RNVS - News) today announced that its Chief Medical Officer, Randall W. Moreadith, M.D., Ph.D., will leave the company effective December 16, 2005. Renovis did not announce immediate plans for replacement of the position.
"We are grateful to Randall for his leadership in completing multiple clinical trials for drug candidates that were under development by Renovis during his tenure, and wish him well in his future endeavors," said Corey S. Goodman, Ph.D., President and Chief Executive Officer.
Renovis also announced today that in accordance with NASDAQ Marketplace Rule 4350, it issued new inducement stock options to two non-executive employees hired during November 2005 to join the company's drug discovery efforts. The inducement stock options, covering an aggregate 4,100 shares of common stock, were granted without stockholder approval pursuant to NASDAQ Marketplace Rule 4350 (i)(1)(A)(iv). These options are classified as non-qualified stock options and were granted with Renovis' standard stock option terms, including a 10-year term and four-year vesting, at exercise prices equal to the fair market value on the date of grant.<<
snip
Cheers, Tuck |
